Twenty-five trials were selected from the Clinical Trials Registry including 7 phase III chemotherapy trials, 11 Phase II targeted therapy trials, 3 immune therapy trials, 1 mammalian target of rapamycin (mTOR) inhibitor trial, and 3 gene and vaccine therapy trials.
The use of multiple native or recombinant proteins in diagnosis has an important impact on the price of immune-trial kits.
This might be due to the fact, that in contrast to other GV1001 immunization trials, no clear immune responses (DTH or T cell responses) have been observed in this study.
The public interest in understanding a torturer's claim to be immune from trial on health grounds is compelling.
For example, in October, 2009, the high court declared unconstitutional a new law that would have made certain institutional figures, including the Prime Minister, immune from trial during their period of office.
While he waited for a tumor sample from Mr. Bucksbaum's neck for B-RAF screening, Dr. Flaherty secured him a spot on an immune therapy trial.
One immune therapy trial was selected from the Clinical Trials Registry as described in Table 5.
We have reviewed all the completed immune therapy trials in prostate cancer and highlight important considerations for the next generation of clinical trials.
These criteria were not specifically fulfilled for mTOR inhibitor and immune therapy trials.
Though his long life was not entirely immune to trials, each crisis seemed to propel him to a higher level of greatness.
Significant advances have been made in the field of cancer immunotherapy over the last decade, and many nonrandomised, phase II, immune-targeted trials have shown that immunotherapy can confer survival benefits, although these benefits were not confirmed in phase III trials (Rosenberg et al, 2004; Sabbatini and Odunsi, 2007).
